Evotec SE ADR (EVO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $561.51M
Last updated: Nov 17, 2026 at 4:10 PM ET
Evotec SE ADR (EVO) Statistics
Evotec SE ADR (EVO) has a market cap of $561.51M. It kept -25.37% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $561.51M |
|---|---|
| Latest price (Nov 17, 2026) | $1.48 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.6x and 0.7x. Its year-end P/S ranged from 0.9x to 4.9x from 2022 to 2025.
| P/S Ratio | 0.6x |
|---|---|
| P/B Ratio | 0.7x |
| P/TBV Ratio | 1.4x |
Price Statistics
The stock is down 50.99% over 52 weeks and trades 6.33% below its 50-day average.
| Beta (1Y) | 1.15 |
|---|---|
| 52-Week Change | -50.99% |
| 1-Month Change | +4.23% |
| 3-Month Change | -25.25% |
| 6-Month Change | -46.76% |
| 5-Year Change | -93.63% |
| 10-Year Change | -43.65% |
| Total Return (1Y) | -50.99% |
| Total Return (3Y CAGR) | -47.25% |
| Total Return (5Y CAGR) | -42.77% |
| Return vs SPY (1Y) | -61.56% |
| Max Drawdown (1Y) | -65.25% |
| Max Drawdown (3Y) | -88.69% |
| Sharpe Ratio (1Y) | -1.23 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $1.58 |
| 200-Day Average | $2.40 |
| 52-Week Range | $1.33 to $3.87 |
| RSI (14 Days) | 41.1 |
| Average Volume (20 Days) | 73.47K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.32x current liabilities, and total debt is 0.65x shareholder equity.
| Current Ratio | 2.32x |
|---|---|
| Quick Ratio | 2.19x |
| Debt / Equity | 0.65x |
| Interest Coverage | -11.83x |
Returns and Efficiency
Return on invested capital is -15.11% over the last 12 months, against a 5-year average of -3.20%.
| Return on Equity (ROE) | -28.95% |
|---|---|
| Return on Assets (ROA) | -12.34% |
| Return on Invested Capital (ROIC) | -15.11% |
| Return on Capital Employed (ROCE) | -12.99% |
| ROE (5Y Average) | -7.89% |
| ROA (5Y Average) | -3.53% |
| ROIC (5Y Average) | -3.20% |
| Asset Turnover | 0.44x |
| Inventory Turnover | 16.69x |
| Receivables Turnover | 6.16x |
| Cash Conversion Cycle | 53 days |
Scores
EVO has an Altman Z-Score of -0.14, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.14 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of EUR 723.27M over the last 12 months is down 4.37% from the 12 months before.
| Revenue | EUR 723.27M |
|---|---|
| Revenue Growth (YoY) | -4.37% |
| Gross Profit | EUR 95.06M |
| Operating Income | EUR -98.23M |
| Pretax Income | EUR -165.67M |
| Net Income | EUR -183.48M |
| EBIT | EUR -158.44M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 42.78% of the EUR 1.50B in total assets.
| Working Capital | EUR 377.62M |
|---|---|
| Shareholder Equity | EUR 641.66M |
| Tangible Book Value | EUR 334.43M |
| Total Assets | EUR 1.50B |
| Total Liabilities | EUR 863.31M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After EUR 37.08M of capital spending, operating cash flow left EUR -129.77M of free cash flow.
| Operating Cash Flow | EUR -92.69M |
|---|---|
| Capital Expenditures | EUR 37.08M |
| Free Cash Flow | EUR -129.77M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -13.58%, against a 5-year average of -8.01%.
| Gross Margin | 13.14% |
|---|---|
| Operating Margin | -13.58% |
| Pretax Margin | -22.91% |
| Net Margin | -25.37% |
| EBIT Margin | -21.91% |
| FCF Margin | -17.94% |
| Gross Margin (5Y Average) | 18.56% |
| Operating Margin (5Y Average) | -8.01% |
| Net Margin (5Y Average) | -7.40% |
Growth
Revenue grew 0.26% a year over 3 years.
| Revenue Growth (3Y CAGR) | +0.26% |
|---|---|
| Revenue Growth (5Y CAGR) | +8.62% |
Stock Splits
The last split was a 4-for-1 forward split on Oct 20, 2021.
| Last Split Date | Oct 20, 2021 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 4:1 |
Peer Position
Against 10 similar companies, EVO has the 9th highest P/S.
P/S RatioPeer median 1.8x
ROICPeer median 1.48%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.87%
| P/S Ratio | 0.6x vs 1.8x median |
|---|---|
| ROIC | -15.11% vs 1.48% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -4.37% vs +13.87% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EVO
What is EVO's market cap?
Evotec SE ADR has a market cap of $561.51M.
How many shares of EVO are outstanding?
Evotec SE ADR has 355.53M shares outstanding. The count is up 0.05% from a year earlier.
Does EVO pay a dividend?
No. Evotec SE ADR does not pay a dividend.
EVO pages: Overview, Charting, Financials, Statistics, Valuation, Competitors